The chronic kidney disease drug development landscape is evolving at an unprecedented pace, driven by breakthrough approvals, billion-dollar mergers and acquisitions, and increasing regulatory support ...

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) was downgraded by stock analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Monday.

Cantor Fitzgerald reaffirmed its Overweight rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with a consistent price target of $480.00. According to InvestingPro data, Vertex, a prominent ...

Objectives Ethnicity and health outcomes are intrinsically interrelated, although mechanisms are complex. SLE is a disease ...